Melanotan I for UV Photoprotection

Candidate profile

Individuals with fair skin (Fitzpatrick type I-III) who experience disproportionate UV sensitivity — frequent sunburns, polymorphic light eruption, or occupational/recreational UV exposure that exceeds their innate photoprotective capacity. Also relevant for individuals with erythropoietic protoporphyria (EPP) or other photosensitivity disorders where UV avoidance significantly impairs quality of life.

Not appropriate as a substitute for topical sun protection in the general population. Melanotan I augments endogenous melanin production — it does not eliminate UV damage risk. Sunscreen, protective clothing, and UV-avoidance behavior remain the foundation of photoprotection.

Relevant clinical contexts include:

• Fitzpatrick type I individuals (always burns, never tans) who work or recreate outdoors
• Polymorphic light eruption (PLE) sufferers seeking to reduce flare frequency
• Erythropoietic protoporphyria (EPP) patients with severe phototoxic reactions
• Individuals with personal or family history of non-melanoma skin cancer seeking additional UV defense layers
• Outdoor athletes, agricultural workers, or construction professionals with occupational UV exposure exceeding practical sunscreen reapplication capacity

Important distinction: Melanotan I (afamelanotide) is a selective MC1R agonist with a well-defined pharmacological profile. It should not be confused with Melanotan II, which activates multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R) and produces a broader — and less predictable — range of effects including sexual arousal, appetite suppression, and nausea.

Approach

Subcutaneous Melanotan I (afamelanotide) administration to stimulate eumelanin synthesis in epidermal melanocytes. Eumelanin is the brown-black pigment responsible for constitutive skin photoprotection. By activating MC1R on melanocytes, Melanotan I upregulates tyrosinase activity and melanin synthesis independently of UV exposure — producing a "base tan" effect that increases the skin's UV absorption capacity before sun exposure occurs.

The eumelanin distinction is important: UV exposure alone triggers both eumelanin and pheomelanin synthesis. Pheomelanin (red-yellow pigment) actually generates reactive oxygen species under UV exposure, potentially contributing to DNA damage. Melanotan I preferentially stimulates eumelanin, which provides genuine UV absorption without the pro-oxidative liabilities of pheomelanin. This makes the MC1R-mediated tanning pathway qualitatively superior to UV-induced tanning for photoprotection purposes.

Protocol design

Peptide: Melanotan I (afamelanotide)

Route: Subcutaneous injection

Dose: 0.5-1.0 mg daily during the loading phase

Loading phase (weeks 1-3): 0.5 mg daily subcutaneous. Start at the lower dose to assess tolerance and skin response. Increase to 1.0 mg daily if pigmentation response is insufficient and the peptide is well-tolerated.

Maintenance phase (weeks 4-8): 0.5 mg every other day, or 3 times weekly. Once visible melanogenesis is established, reduced frequency maintains pigmentation.

Duration: 8-12 weeks for seasonal photoprotection. Timing should begin 3-4 weeks before the anticipated period of maximum UV exposure.

Pharmaceutical reference: The approved pharmaceutical form (Scenesse) uses a 16 mg subcutaneous implant releasing afamelanotide over approximately 60 days. The injectable protocol described here approximates the pharmacokinetic exposure using reconstituted peptide.

Reconstitution: Reconstitute lyophilized powder with bacteriostatic water. Typical reconstitution: 2 mL bacteriostatic water to a 10 mg vial = 5 mg/mL. A 1.0 mg dose = 0.2 mL. Use insulin syringes for accurate low-volume dosing.

Storage: Refrigerate reconstituted solution. Use within 4 weeks. Protect from light — melanocortin peptides can degrade with light exposure.

Injection sites: Abdominal subcutaneous. Rotate sites to avoid local lipodystrophy with repeated injections.

Expected timeline

Week 1: Minimal visible pigmentation change. Melanocyte activation is occurring at the cellular level — tyrosinase upregulation and melanin synthesis have begun, but melanin granule transfer to keratinocytes takes time. Some individuals notice slight darkening of existing moles or freckles as melanocytes with higher baseline activity respond first.

Weeks 2-3: Visible pigmentation increase. A gradual, even tanning effect emerges independent of UV exposure. The pigmentation is eumelanin-dominant (brown-black) rather than pheomelanin (red-yellow), providing genuine photoprotective benefit. Fitzpatrick I individuals may progress to a type II-III equivalent; type II individuals may reach type III-IV photoprotective capacity.

Weeks 4-6: Pigmentation plateau. The maximum melanogenic response at a given dose is typically reached by week 4-6. The protective effect is measurable: studies show a 3-4 fold increase in minimal erythema dose (MED) — the UV threshold for sunburn — in treated individuals.

Weeks 7-12 (maintenance): Sustained pigmentation with reduced dosing frequency. Melanin has a half-life of approximately 2-3 weeks in the epidermis (tied to keratinocyte turnover), so discontinuation results in gradual fading over 4-8 weeks.

Post-cycle: Pigmentation fades gradually as melanin-containing keratinocytes undergo normal turnover. The rate of fading depends on anatomical location (sun-exposed areas retain pigment longer due to UV-stimulated melanin maintenance) and individual turnover rate. For year-round photoprotection, seasonal cycling is common — start the protocol 3-4 weeks before the high-UV season and maintain through the exposure period.

Concurrent photoprotection strategy

Melanotan I augments one layer of a multi-layer photoprotection approach. It does not replace other measures:

• Topical sunscreen: Broad-spectrum SPF 30-50, applied to exposed skin during outdoor activity. Melanotan I increases the skin's innate UV absorption but does not provide sufficient protection for extended UV exposure alone.
• Protective clothing: UPF-rated clothing, wide-brim hats, and UV-blocking sunglasses remain the most reliable UV barriers. Melanin does not protect the eyes.
• UV timing awareness: Avoid peak UV hours (10 AM - 4 PM) when possible. The UV index determines actual risk — melanin provides proportionally less protection at very high UV index levels.
• Antioxidant support: Oral antioxidants (vitamin C, vitamin E, astaxanthin) may complement photoprotection by neutralizing free radicals generated by UV that penetrates beyond the melanin barrier. Topical vitamin C (L-ascorbic acid 15-20%) provides additional UV-damage mitigation.
• Regular skin examinations: Annual dermatological examination with dermatoscopy, plus self-examination monthly. Document any new or changing lesions.

Complementary peptides

• GHK-Cu (topical): Copper peptide that supports skin repair and collagen remodeling. May complement photoprotection by enhancing the skin's repair capacity for any UV damage that does occur despite increased melanin.
• Thymosin Beta-4 (TB-500) (subcutaneous): For individuals combining outdoor activity with injury recovery — no direct interaction with melanogenesis but addresses the tissue repair dimension for active individuals.

Evidence assessment

Melanotan I (as afamelanotide/Scenesse) has the rare distinction among research peptides of having completed the full regulatory pathway — it is EMA-approved for erythropoietic protoporphyria. Phase II and III trials demonstrated significant increase in pain-free time in sunlight and measurable increases in melanin density. For general photoprotection in healthy individuals, the evidence is strong mechanistically (MC1R agonism, eumelanin synthesis) and supported by controlled UV exposure studies showing increased MED. However, off-label use for cosmetic photoprotection has not been evaluated in large-scale safety trials. The peptide has decades of research history and a well-characterized safety profile, but long-term data comes primarily from the EPP population.

Monitoring markers

• Skin pigmentation assessment: visual comparison and/or melanin index measurement (reflectance spectrophotometry) at baseline, week 4, and week 8
• Mole surveillance: document existing nevi at baseline. Monitor for changes in size, shape, or color — melanocyte activation may alter existing nevi
• Minimal erythema dose (MED) testing if available: objective measurement of UV tolerance at baseline and week 6
• Liver function (ALT, AST): baseline and week 8. Melanogenesis involves hepatic processing of melanin precursors
• Blood pressure: monitor periodically. Alpha-MSH analogs have modest cardiovascular effects in some individuals
• Side effect log: nausea severity, flushing duration, and any new symptoms — track for the first 2 weeks to establish individual tolerance profile
• UV exposure log: document sun exposure duration, UV index, and any sunburn events to correlate with melanin-based photoprotection level

Assessment schedule:

• Baseline: full skin assessment, mole mapping (photographic documentation), melanin index if available
• Week 3: visible pigmentation assessment — determine if melanogenic response is occurring
• Week 6: mid-cycle assessment — MED testing if available, mole check for changes
• Week 8-12: end-of-cycle assessment — final pigmentation measurement, comprehensive mole review
• 8 weeks post-cycle: assess pigmentation retention rate to guide future cycle planning

Limitations and considerations

• Not a sunscreen replacement: Increased melanin provides SPF-equivalent protection of approximately 3-4. This reduces burn risk significantly for fair-skinned individuals but does not eliminate it. Topical sunscreen remains necessary for extended UV exposure.
• Mole monitoring is essential: Melanocyte activation raises theoretical concern about nevi changes. Dermatological surveillance before, during, and after use is prudent. No causal link between afamelanotide and melanoma has been established, but the theoretical concern exists because the pathway involves melanocyte proliferation signaling.
• Pigmentation is cosmetically variable: The tanning effect is generally even, but individuals with uneven baseline pigmentation (melasma, post-inflammatory hyperpigmentation) may experience uneven darkening. Dermatological assessment before use is advisable for these individuals.
• Distinction from Melanotan II: Melanotan II activates multiple melanocortin receptors and produces side effects including nausea, facial flushing, sexual arousal, and appetite suppression. Melanotan I is selective for MC1R and has a narrower, more predictable effect profile.
• Regulatory status varies: Scenesse (afamelanotide implant) is approved in the EU and Australia for EPP. Off-label injectable use of Melanotan I occupies a regulatory gray area in most jurisdictions.
• UV exposure is not required but may enhance: Melanotan I stimulates melanogenesis independently of UV, but moderate sun exposure during the protocol may enhance melanin transfer to keratinocytes. This does not mean deliberate sunburning — it means normal outdoor activity without extreme UV avoidance. Sunscreen should still be used during prolonged exposure.
• Individual genetic variation: MC1R polymorphisms (common in Fitzpatrick type I individuals with red hair) can reduce response to MC1R agonists. Individuals with loss-of-function MC1R variants may experience reduced or absent melanogenic response. This cannot be predicted without genetic testing and becomes apparent clinically by week 3 if no pigmentation change occurs.
• Nausea and flushing: The most common acute side effects. Both are typically mild and self-limiting within 30-60 minutes of injection. Reducing the dose or injecting before bedtime (to sleep through the transient effects) are effective management strategies.
• Children and adolescents: No safety data for Melanotan I use in minors. Avoid. Pediatric photosensitivity conditions should be managed under dermatological supervision with conventional photoprotection strategies.
• Pregnancy and lactation: No reproductive safety data. Discontinue before planned conception. Melanocortin receptor activation has theoretical implications for fetal development that have not been studied.
• Duration of use: Long-term safety data beyond 12-month cycles is limited to the EPP patient population. For seasonal photoprotection, limit use to the UV-intense months and allow full pigmentation washout between annual cycles.
• Interaction with phototherapy: If undergoing UV phototherapy for dermatological conditions (psoriasis, vitiligo), Melanotan I use should be coordinated with the dermatologist. The combination alters the UV dose-response relationship and may require phototherapy dose adjustment.
• Cosmetic expectations: The pigmentation produced by Melanotan I is generally natural-appearing — a gradual, even darkening consistent with a moderate tan. However, individuals seeking dramatic tanning results should understand that Melanotan I's selective MC1R agonism produces a more subtle effect than Melanotan II. The benefit is photoprotection quality, not cosmetic intensity.